John Lyle

Looking for new ways to visualize, size, and count proteins, extracellular vesicles (EVs), liposomes, lipid nanoparticles, and viruses? The California NanoSystems Institute at UCLA just enhanced its capabilities with the addition of nanoparticle tracking analysis (NTA) at the Nano and Pico Characterization Laboratory (NPC). The Horiba ViewSizer 3000 tracks nanoparticles in liquid by monitoring their heat-induced Brownian motion. Its three lasers accommodate a wide range of particle sizes (10 nanometers to 15 microns), to provide high-resolution size distribution data, concentration measurements, and tracking of specific particle subsets using fluorescent markers. We invite all researchers to leverage this state-of-the-art instrument! #NanoparticleTracking #BiomedicalResearch #UCLA #Nanotechnology #LiquidBiopsy #ExtracellularVesicles

3

Welcome to CSUBIOTECH Created in 1987, the California State University (CSU) Biotechnology (CSUBIOTECH; https://lnkd.in/gddjG2BF) has the mission of providing vision, leadership and support for biotechnology education and research throughout the CSU to promote biotechnology and economic development in California. The strategic goals of CSUBIOTECH are to promote innovative biotechnology education and research across the CSU system and provide leadership in training California's biotechnology work force. This will enable CSU faculty to become better scholars and instructors, and for undergraduate, graduate and returning students to advance their careers and become leaders in the biotechnology sector in California and across the nation. It will also allow CSUBIOTECH to extend, develop and expand relationships with regional and industrial partners, and enhance general education across the CSU and California for better understanding of biotechnology issues, challenges, and opportunities. CSUBIOTECH provides grants and awards, organizes the annual CSU Biotechnology Symposium, promotes industry-responsive curricular innovations, and serves as a liaison between the CSU and government, regional and biotechnology industry partners, including philanthropic partners. Within CSU, CSUBIOTECH promotes biotechnology workforce development by supporting innovative coursework, real-world research experiences, and core resources for students and faculty across all 23 CSU campuses. The program is cross-cutting involving students, faculty and administrators from life sciences, physical sciences, health sciences, engineering, mathematics, agriculture, business and computer science departments and divisions, and more across the system, including the Chancellor’s Office. In 2008 CSUBIOTECH developed its first three-year strategic plan, approved by the CSU Chancellor to articulate the community’s purpose, values, and goals, while also framing annual operations. In March 2016 CSUBIOTECH was authorized to continue operations as a system-wide affinity group under Executive Order 1103. CSUBIOTECH is administered and managed by an Executive Director, based at SDSU, who reports to the CSU Chancellor through a 6-person Presidents’ Commission (drawn from Presidents of the 23 campuses). The Program Office at SDSU is staffed by an Administrative Support Coordinator, two Administrative Analysts, and a Student Program Assistant. The Program Office is advised and supported by an 18-member Strategic Planning Council comprising faculty and deans from some campuses and external representatives from industry, Govt and non-profit sector, and a 92-member-Faculty Consensus Group comprising of biotechnology faculty representatives and deans from all CSU campuses. Altogether, over 1,000 CSU students, faculty, deans, and administrators interact with the CSUBIOTECH program office yearly.

6

Don’t miss this opportunity at the Gene Therapy Initiative 1st Annual Symposium on September 19, 2024 to engage our thriving San Diego community of researchers, life sciences, biotechnology and pharmaceutical companies in the gene therapy space. The Gene Therapy Initiative (GTI) Symposium will convene researchers and industry experts to share the latest scientific findings and facilitate new partnerships with the goal of expediting the delivery of stem cell and gene therapy treatments, especially for patients with rare genetic diseases. Program Highlights: *Exploratory talks on innovative gene modifying therapeutics and optimization of existing tools. *Updates on gene therapies that are the subject of academic research and commercial development. *Induced Pluripotent Stem-cell-based disease models to test gene therapies. *Interactive panel on resources and collaboration for developing therapies for rare diseases. *Opportunity to learn about 2024 GTI seed grant funded projects. *Poster session featuring faculty and student research. *Networking hour to foster connectivity amongst attendees. Please note, there is NO CME for this symposium.   For more information and to register, go to: https://lnkd.in/gJuEP_Kv #GeneTherapy #genetherapies #RNAtechnologies #ExVivoGeneTherapy #AAVgenetherapy #research #science #lifesciences #biotechnology #scientificmeeting

12

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

🧬 A new study led by biologists at Washington University dives into the mechanisms behind how #cells respond to stress, revealing the key role of the #protein Gcn4 in regulating gene expression to help cells adapt and survive. "How Gcn4 is translated under these conditions was surprising because it is typically produced through a unique translation-based mechanism in response to the integrated stress response (ISR) process," researcher Hani Zaher said. The findings provide valuable insights into the intricate cellular stress response and may have implications for understanding cancer. 🔬 Read more: https://lnkd.in/dRFujWJE #CancerResearch #CellBiology #Insight #BGIGeneTest

10

🧬 Research shows the PaRTI-Seq gDNA-based assay effectively reduced host background and boosts microbial reads, enhancing sensitivity for accurate diagnosis. #Sepsis #mNGS #Innovation https://lnkd.in/gfznKcDx

7

🌟 Study showcases the impact of PaRTI-Seq, a gDNA assay, over cfDNA-based mNGS workflows. https://lnkd.in/gMT4rTU4

11

Congrats to CpG Diagnostics’ founder Bodour Salhia, Ph.D & University of Southern California researchers for developing a blood test for early-stage ovarian cancer! CpG Diagnostics (2023 Cohort) is working to expand the liquid biopsy approach to ovarian cancer, a disease that is particularly difficult to diagnose. Early detection of cancer by liquid biopsy holds the potential to dramatically improve outcomes for patients by helping physicians diagnose and begin treatment earlier in the progression of the disease — perhaps even before patients exhibit symptoms. Join us in celebrating CpG Diagnostics, Founder & CEO Bodour Salhia, Ph.D, and the team for achieving this major milestone and their positive impacts in the realm of #cancerresearch! Read more about CpG Diagnostics in our April Newsletter: https://lnkd.in/gUznyX6T 📩 Sign up for our mailing list: https://lnkd.in/gtcdE6J2 #Sustainability #Innovation #Healthcare #CancerResearch #ClimateTech #LartaInstitute

14

2 Comments

Inferring gene regulatory networks from single-cell transcriptomics based on graph embedding https://lnkd.in/gBumkaS9

46

NAMI Oregon is proud to join Neurocrine Biosciences in supporting #TDAwarenessWeek, running from May 5-11. Tardive Dyskinesia (TD) is a condition characterized by persistent, involuntary movements affecting various parts of the body, such as the face, torso, limbs, and fingers or toes. These movements can vary from rapid and jerky to slow and writhing, significantly impacting those affected by TD. TD is often associated with prolonged use of antipsychotic medication, which may be necessary to treat mental illnesses like major depressive disorder and bipolar disorder. Approximately 600,000 Americans live with TD, and around 65% of them are undiagnosed. Let's raise awareness together and support those living with TD during #TDAwarenessWeek. Learn more at https://lnkd.in/g-atBE4x or www.TalkAboutTD.com.

1

Frontier Science - RNA Binding Proteins (RBPs) w/ Gene Yeo - Professor @ UC San Diego Delve into the forefront of RNA Biology and Therapeutics with BIOS Frontier Science! Join us as we engage in a profound discussion with esteemed Professor Gene Yeo from UC San Diego. In this episode, we'll explore the intricate landscape of RNA Binding Proteins (RBPs), shedding light on their crucial role in gene expression regulation and their promising potential as therapeutic targets. From cutting-edge technologies like eCLIP and STAMP to innovative RNA editing therapies, we'll unveil the latest advancements shaping the landscape of modern medicine. Tune in to embark on this enlightening journey Tune in: https://buff.ly/3JM7fIm #Biotech #RNA #Therapeutics #SciencePodcast

2

As a selected Showcase Company from the NCI SBIR Development Center's Investor Initiative, Tezcat Biosciences will be at #BIO2024 in San Diego June 3-6. Tezcat Biosciences is developing a receptor-independent drug delivery technology, initially positioned for RAS pathway activated cancers. We are seeking industry collaborations to expand our pipeline as our technology is payload and disease agnostic. If your company has an interesting, hard to deliver payload and/or works in the following disease areas, we would like to set up a time to meet at the event. #SmallMolecule #siRNA #Radiopharmaceutical #PROTAC #Immunomodulatory #EndosomeEscape #CardiovascularDisease #MASH #NASH #InflammatoryDisease #NeurodegenerativeDisease #InfectiousDisease #AnimalHealth To schedule a time to meet inside the event, please use BIO’s One-on-One Partnering™ System. Outside the event, please DM either Dr. Craig Ramirez, Ph.D. or Dr. Andrew D. Hauser to schedule a time to meet. #biotech #businessdevelopment #networking #partnering https://lnkd.in/eEDtKaAK

14

In the Quantitative Biosciences Institute, UCSF Coronavirus Research Group (QCRG), Nevan Krogan, PhD, built a transdisciplinary, multi-lab, multi-institutional, multi-national, multi-sector open-science consortium in which over a thousand trainees and senior investigators worked together—overcoming virtually every barrier that fragments science and the science community. Read more about the challenges academic research faces when it comes to breaking down silos, and about how facilitating collaboration is the solution, in this Q&A with the UCSF SCHOOL OF MEDICINE Department of Cellular and Molecular Pharmacology faculty member. https://lnkd.in/gg4D39FB

2

Recognizing the signs and symptoms of chronic myeloid leukemia (CML) is essential for effective management. Early detection and understanding of key indicators play a crucial role in creating appropriate treatment strategies and improving outcomes for individuals with CML. Learn more about CML from the American Cancer Society at https://lnkd.in/eZfjAhe2 #CancerResearch #CancerResearchMonth #NCRM24

3

Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer This paper by Brian Koh and several co-authors at PrognomiQ Inc represents the largest deep multi-omics interrogation to date for lung cancer. Proteomics sample processing leveraged the Seer Proteograph Assay using a 5-nanoparticle panel followed by LC-MS analysis using a fleet of four Evosep One LC platforms from Evosep Biosystems coupled to Bruker timsTOF HT Mass Spectrometers. Samples from a cohort of 2,513 subjects was leveraged in an untargeted approach to collect and analyze over 750,000 orthogonal protein, transcript, and metabolite features to train a machine learning-based lung cancer classifier. You can read the full manuscript here: https://lnkd.in/eEcSFV3M To learn more about the Evosep One platform, visit our website www.evosep.com or reach out to me for more information.

71

1 Comment

A recent review highlighting the potential of mcfDNA-based metagenomics like The Karius Test to diagnose C. bantiana brain abscess. https://lnkd.in/gjbZQRjq #ngs #microbiologicaldiagnosis #cellfreeDNA #cfDNA #mcfDNA #microbialcellfreeDNA #diagnostics #clinicaldiagnostics #infectiousdisease #infection #metagenomicsequencing #moleculardiagnosis #diagnosis #metagenomics #liquidbiopsy #infections #healthcareinnovation #microbiology #noninvasive #rapiddiagnosis #rapidtest #sequencing #fungi #melanizedfungus #brainabscess #abscess #phaeohyphomycosis #cladophialophora

4

BacStich DNA CSO Sasha Levy, PhD, is at SynBioBeta's Synthetic Biology Conference in San Jose this week to speak on the MITRE sponsored panel "BioNet: Creating a Distributed SynBio Ecosystem for Everyone" on May 8th from 1:45-2:30. Come by and say hi! SynBioBeta MITRE #syntheticbiology #dnasynthesis

6

1 Comment

Going to Oxford Global, Spatial Biology, East Coast 2024? I'll be there to discuss what NeoGenomics Laboratories is doing to advance the integration of #spatialbiology into clinical trials today. Stop by our booth or come to our talk and let us help you further your translational pipeline. #spatial, #multiomics, #tumormicroenvironment, #biomarkers

27

1 Comment